- Global Pharma News & Resources

Study reported in BMC Gastroenterology shows significantly better performance characteristics of Epigenomics' liver cancer panel compared to the current standard of care for the early detection of HCC

DGAP-News: Epigenomics AG / Key word(s): Study results/Study
06.04.2021 / 07:59
The issuer is solely responsible for the content of this announcement.

Study reported in BMC Gastroenterology demonstrates significantly better performance characteristics of Epigenomics' liver cancer panel compared to the current standard of care for the early detection of hepatocellular carcinoma (HCC) in patients with liver cirrhosis

  • The Epigenomics next generation sequencing (NGS) liver cancer panel plus alpha-fetoprotein (AFP) had a sensitivity of 68% at a specificity of 97% compared to the current standard of care (ultrasound and AFP) of 63% sensitivity and 84% specificity
  • Hepatocellular carcinoma is the leading cause of death in patients with cirrhosis, particularly due to lack of early detection

Berlin (Germany) and San Diego, CA (U.S.A.), April 6, 2021 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") announces that a study recently published in BMC Gastroenterology shows that the Epigenomics new liver cancer panel represents a new and valuable alternative for the early detection of hepatocellular carcinoma (liver cancer, HCC) in cirrhotic patients.

Greg Hamilton, CEO of Epigenomics AG, commented: "HCC is in the top 10 of most common cancers in both men and women worldwide, occurring in approximately 4.5 million U.S. adults. In addition, HCC is considered the second leading cause of cancer-related deaths world-wide with more than 780,000 deaths annually. However, early detection offers a good chance of curative treatment. The performance of the currently recommended surveillance methods, however, are suboptimal, as are the low participation rates in surveillance. In this respect, we are very pleased with the results of the study, as it demonstrates that our liver cancer panel can address the significant clinical need for novel minimally invasive testing to aid in the detection of HCC at an early stage, and thus save lives."

The study compared patients with cirrhosis who had early-stage treatable liver cancer with patients having cirrhosis but no cancer. As reported in the study, when combined with AFP (alpha-fetoprotein) measurement in an ad hoc analysis, the new Epigenomics Next Generation Sequencing (NGS) panel achieved a sensitivity of 68 % at a specificity of 97 %.

The current standard of care for HCC surveillance is ultrasound plus AFP with a sensitivity of 63% and a specificity of 84%. Consequently, the Epigenomics' blood-based panel provides a very simple and affordable method that may improve clinical performance and could be particularly applicable in settings where resources for surveillance by imaging may be limited. Such a blood test can help detect HCC at an early stage and thus prevent cancer-related deaths, because after all, patients' chances of survival decrease rapidly if the disease is detected late.


About Epigenomics
Epigenomics AG is a molecular diagnostics company focused on blood testing for the early detection of cancer. Based on its proprietary biomarker technology for the detection of methylated DNA, Epigenomics develops and markets blood tests for various cancer indications with high unmet medical need. Epigenomics' lead product is the blood test Epi proColon(R) for the early detection of colorectal cancer. Epi proColon is approved by the U.S. Food and Drug Administration (FDA) and is marketed in the United States and Europe as well as other selected countries. HCCBloodTest, a blood test for the detection of liver cancer, have received the CE Mark for marketing in Europe.

For further information please visit


Epigenomics AG, Geneststrasse 5, 10829 Berlin,
Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, E-Mail:

Investor Relations
IR.on AG, Frederic Hilke, Tel +49 221 9140 970, E-Mail:


Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any expected results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.


06.04.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

Language: English
Company: Epigenomics AG
Geneststra├če 5
10829 Berlin
Phone: +49 30 24345-0
Fax: +49 30 24345-555
ISIN: DE000A3H2184
WKN: A3H218
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1180832

End of News DGAP News Service

Editor Details

Last Updated: 06-Apr-2021